Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...

Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...

Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Real-world study of GLP-1 patients continues to deliver leading insights

Manufacturer: Ferring / Seikagaku Proposed indications Radicular leg pain associated with lumbar disc herniation (LDH) Clinical overview Mechanism of action Condoliase, also known as chondroitin...

Manufacturer: Abeona Proposed indications Recessive dystrophic epidermolysis bullosa (RDEB) Clinical overview Mechanism of action Prademagene zamikeracel (pz-cel) is an autologous, collagen type...

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Configure the table properties *Orphan drug status #chimeric antigen receptor T cell (CAR T) therapy intravenous (IV); Prescription Drug User Fee Act (PDUFA) Cell therapy: Aims to replace or repair...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...

cover image for Quarterly Drug Pipeline: January 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2026...

cover images for Quarterly Drug Pipeline: April 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2026 Prime...

Cover image for Quarterly Drug Pipeline: July 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2026 Prime...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the cost impact of GLP-1 medications, offering critical...

Emerging evidence shows GLP-1 therapies improve health outcomes, but questions remain about their long-term impact on total health care costs

Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Editor's message Gene therapy= Aims to fix a faulty gene or replace it with a healthy gene to try to cure a disease or help the body become better at fighting disease Maryam Tabatabai, PharmD...

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Award-winning research from Prime Therapeutics highlighted significant gains in one-year persistence rates for GLP-1 weight-loss therapies among commercially insured adults

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access

Prime Therapeutics experts examine how GLP-1 discontinuation trends shape benefit strategies, patient outcomes and long-term affordability

cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-june-2026 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

Live updates from AMCP Annual Meeting

Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...

Cover for 2023 January Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jan?fr=sODMzODc3NDc1ODQ About...

Cover for 2023 April Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_apr?fr=xKAE9_zU1NQ About Prime...

Cover for 2023 July Quarterly Pipeline a view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jul?fr=sMjFiMTc3NDc1ODQ About...

Cover for 2023 October Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_oct?fr=sMTIyZTc3NDc1ODQ About...